Compass Therapeutics, Inc.
CMPX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $42 | $38 | $30 | $20 |
| G&A Expenses | $15 | $12 | $12 | $11 |
| SG&A Expenses | $15 | $12 | $12 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $51 |
| Operating Expenses | $57 | $50 | $42 | $82 |
| Operating Income | -$57 | -$50 | -$42 | -$82 |
| % Margin | -6,661.8% | – | – | – |
| Other Income/Exp. Net | $7 | $8 | $2 | -$0 |
| Pre-Tax Income | -$49 | -$42 | -$39 | -$82 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$49 | -$42 | -$39 | -$82 |
| % Margin | -5,808.8% | – | – | – |
| EPS | -0.36 | -0.33 | -0.35 | -1.31 |
| % Growth | -9.1% | 5.7% | 73.3% | – |
| EPS Diluted | -0.36 | -0.33 | -0.35 | -1.31 |
| Weighted Avg Shares Out | 137 | 127 | 105 | 63 |
| Weighted Avg Shares Out Dil | 137 | 127 | 105 | 63 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $0 | $2 | $0 |
| Interest Expense | $0 | $0 | $2 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$55 | -$48 | -$40 | -$80 |
| % Margin | -6,455.5% | – | – | – |